What's Happening?
CND Life Sciences has been awarded a $3 million grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program. The grant will fund a three-year multicenter study
to determine if the presence of phosphorylated alpha-synuclein (P-SYN) in patients with essential tremor (ET) predicts the likelihood of developing Parkinson's disease (PD). The study will utilize CND's Syn-One Test, a skin biopsy test, to assess the risk of PD in ET patients. The study aims to provide insights into the progression of PD and improve treatment plans for patients.
Why It's Important?
This study could significantly impact the treatment and management of essential tremor and Parkinson's disease. With over seven million people in the U.S. affected by ET, understanding the risk of developing PD is crucial for early intervention and treatment. The Syn-One Test could become a valuable tool for predicting PD risk, potentially leading to earlier and more effective treatments. This research aligns with the industry's move towards developing novel therapies for neurodegenerative diseases.
What's Next?
The study will involve approximately 300 participants and is set to begin recruitment and enrollment in December 2025. It will be conducted at 15 sites across the U.S., including Baylor University Medical Center and Beth Israel Deaconess Medical Center. The results could lead to new diagnostic and treatment strategies for ET and PD, providing physicians with better tools to manage these conditions.
Beyond the Headlines
The study highlights the importance of early detection and intervention in neurodegenerative diseases. By identifying patients at risk for PD, healthcare providers can tailor treatment plans to delay or prevent the onset of the disease. This research also underscores the potential of biomarker-based diagnostics in transforming patient care.
